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Abstract
Background: The Zeus® (Dräger, Lübeck, Germany), an automated closed-circuit anesthesia machine, uses high
fresh gas flows (FGF) to wash-in the circuit and the lungs, and intermittently flushes the system to remove
unwanted N2. We hypothesized this could increase desflurane consumption to such an extent that agent
consumption might become higher than with a conventional anesthesia machine (Anesthesia Delivery Unit
[ADU®], GE, Helsinki, Finland) used with a previously derived desflurane-O2-N2O administration schedule that
allows early FGF reduction.
Methods: Thirty-four ASA PS I or II patients undergoing plastic, urologic, or gynecologic surgery received
desflurane in O2/N2O. In the ADU group (n = 24), an initial 3 min high FGF of O2 and N2O (2 and 4 L.min-1,
respectively) was used, followed by 0.3 L.min-1 O2 + 0.4 L.min-1 N2O. The desflurane vaporizer setting (FD) was
6.5% for the first 15 min, and 5.5% during the next 25 min. In the Zeus group (n = 10), the Zeus® was used in
automated closed circuit anesthesia mode with a selected end-expired (FA) desflurane target of 4.6%, and O2/N2O
as the carrier gases with a target inspired O2% of 30%. Desflurane FA and consumption during the first 40 min
were compared using repeated measures one-way ANOVA.
Results: Age and weight did not differ between the groups (P > 0.05), but patients in the Zeus group were taller
(P = 0.04). In the Zeus group, the desflurane FA was lower during the first 3 min (P < 0.05), identical at 4 min (P
> 0.05), and slightly higher after 4 min (P < 0.05). Desflurane consumption was higher in the Zeus group at all
times, a difference that persisted after correcting for the small difference in FA between the two groups.
Conclusion: Agent consumption with an automated closed-circuit anesthesia machine is higher than with a
conventional anesthesia machine when the latter is used with a specific vaporizer-FGF sequence. Agent
consumption during automated delivery might be further reduced by optimizing the algorithm(s) that manages the
initial FGF or by tolerating some N2 in the circuit to minimize the need for intermittent flushing.
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Background
Low flow techniques reduce anesthetic agent consump-
tion but are often perceived as cumbersome. First, fre-
quent vaporizer (FD) or fresh gas flow (FGF) adjustments
are thought to be needed, especially at the beginning,
when initial wash-in and high uptake by the patient rap-
idly alter the concentrations of anesthetic gases in the cir-
cle system. Second, when FGF is lowered below minute
ventilation, a discrepancy develops between the delivered
and the inspired concentrations of gases and vapors,
which has been considered as "lack of control". Finally,
the older literature has been preoccupied by the use of
rather complex uptake models to administer these agents
with closed-circuit anesthesia (CCA) techniques. The
administration schedules in the appendix of the mono-
graph by Lowe and Ernst are daunting to the clinician [1].
The Zeus® anesthesia machine (Dräger, Lübeck, Germany)
black-boxes these issues for the clinician by administering
inhaled agents by automated closed-loop end-expired
feedback [2]. However, the Zeus® also has to use a high
FGF, initially to wash-in the circuit and the lungs, and
later to intermittently flush the circuit to remove
unwanted N2. Because this use of high FGF periods
increases desflurane consumption above true CCA condi-
tions, we hypothesized that desflurane consumption with
a conventional anesthesia machine (ADU® or Anesthesia
Delivery Unit, GE, Helsinki, Finland) might be lower than
with the Zeus® if used with a previously derived desflu-
rane-O2-N2O FD-FGF schedule that allows very early FGF
reduction [3,4]. The desflurane concentrations resulting
from the use of that particular administration schedule
with the ADU anesthesia machine have been presented
[4], and in this manuscript we present only those data per-
tinent to the current study.
Methods
After obtaining IRB approval and informed consent, 36
ASA PS I or II patients undergoing plastic, urologic, or
gynecologic surgery were enrolled. All patients received
oral alprazolam 1 h before the scheduled start of surgery.
After preoxygenation (8 L.min-1 O2 FGF for 3 min), propo-
fol (3 mg.kg-1), rocuronium (0.7 mg.kg-1), and sufentanil
(0.1 μg.kg-1) were administered intravenously. After intu-
bation of the trachea, ventilation was mechanically con-
trolled. Initial tidal volume and respiratory rate was 500
mL and 10 breaths per minute, respectively; these settings
were later adjusted at the discretion of the attending
anesthesiologist. Anesthesia was maintained with desflu-
rane in O2-N2O, and additional sufentanil was allowed to
be given. Patients were assigned to one of two groups,
depending on the anesthesia machine and low flow tech-
nique that was used.
In the ADU group (n = 26), an ADU anesthesia machine
(Anesthesia Delivery Unit, GE, Helsinki, Finland) was
used. Desflurane and O2-N2O were administered with a
particular two-step vaporizer-FGF sequence, details of
which have been previously described [4]. Briefly, an ini-
tial 3 min high FGF of O2 and N2O (2 and 4 L.min-1,
respectively) was followed by 0.3 L.min-1 O2 + 0.4 L.min-1
N2O. In patients weighing more than 95 kg, a 4 min high
FGF period was used. Desflurane FD was 6.5% for the first
15 min, and 5.5% during the next 25 min. In- and expira-
tory gases were analyzed by a multigas analyzer (Datex-
Ohmeda Compact Airway Module M-CAiOV, Datex-
Ohmeda, Helsinki, Finland) and downloaded in a spread-
sheet every minute. Gases sampled by the multigas ana-
lyzer (200 mL.min-1) were not redirected to the anesthesia
circuit to avoid N2 accumulation [5]. In the Zeus group (n
= 10), the automated CCA mode was selected with a des-
flurane FA target of 4.6% and O2-N2O as the carrier gas
with an FIO2 target of 30%; 4.5% could not be selected
because the desflurane target can only be increased with
0.2% increments. Concentrations of the in- and expira-
tory gases and agent use were downloaded via the propri-
etary software in a spreadsheet every minute.
Desflurane consumption with the Zeus®  machine was
retrieved form the amount of agent the injector has
injected into the anesthesia circle system, information
that was downloaded to a laptop computer in an Excel file
every 10 seconds. With the ADU®, desflurane consump-
tion was first calculated as mL vapor from FGF and vapor-
izer output (not dialed concentrations); this amount of
vapor is easily converted to mL liquid desflurane (1 mL
liquid desflurane equals 209.3 mL vapor at 20°C). The
same ADU anesthesia machine was used throughout the
study. Vaporizer output was intermittently measured at
the common gas outlet, and could be related to the dialed
concentration as [desflurane vaporizer output (%) = 0.10
+ 0.97* vapor setting] – see reference 4 for details.
All results are presented as mean ± standard deviation.
Desflurane consumption (retrieved directly from both
machines) and desflurane FAduring the first 40 min were
compared using repeated measures one-way ANOVA,
with P < 0.05 indicating statistical significance.
Results
Age, height, weight, and Body Mass Index (BMI) were 54
± 12 years, 167 ± 8 cm, 73 ± 12 kg, and 24 ± 6 kg/m2 in
the ADU and 51 ± 16 years, 174 ± 9 cm, 73 ± 17 kg, and
24 ± 4 kg/m2 the Zeus group, respectively. Age, weight,
and BMI did not differ between the groups (P > 0.05), but
patients in the Zeus group were taller (P = 0.04).
In the ADU group, FAdes was 3.71 ± 0.40% after 1 min,
reached 4.53 ± 0.38% after 2 min and 40 seconds, and fell
to a nadir of 4.03 ± 0.39% 4 min after lowering the FGF
(figure 1); after 15 min, FAdes had gradually increased toBMC Anesthesiology 2008, 8:4 http://www.biomedcentral.com/1471-2253/8/4
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4.40 ± 0.44% and remained almost constant during the
ensuing 30 min (4.50 ± 0.36% after 45 min). The average
desflurane FA of all patients combined between 5 and 40
min was 4.41% (standard deviation 0.43), slightly lower
than the 4.6% target in the Zeus group. The course of
FAN2O and FAN2 in the ADU group are presented in figure
2.
In the Zeus group, desflurane FA (figure 1) was lower than
in the ADU group during the first 3 min (P < 0.05), iden-
tical at 4 min (P > 0.05), and slightly higher after 4 min (P
< 0.05). The FA target was maintained at 4.6% after 4 min
in all patients in the Zeus group. In the Zeus group, the
course of FAN2O is less consistent between patients than
in the ADU group (compare figures 2 and 3) because high
and low FGF alternate, steered by the proprietary algo-
rithms of the Zeus® to combine the goals of achieving the
desired target concentrations of the anesthetic gases and
minimizing agent and gas consumption. A typical exam-
ple of fresh gas flow management by the Zeus® and result-
ing in-expired O2(FIO2), end-expired N2O (FAN2O), and
inspired N2 (FIN2) concentrations are presented in figure
3.
Desflurane consumption was higher in the Zeus than in
the ADU group at all times (Table 1); this difference per-
sisted after correcting for the small difference in FA
between the two groups.
Discussion
The use of a specific desflurane-O2-N2O FD-FGF sequence
with a conventional anesthesia machine provides compa-
rable end-expired desflurane concentrations and reduces
desflurane consumption below that with an automated
CCA machine, or alternatively, desflurane consumption
during automated closed-circuit delivery is higher than
with a conventional anesthesia machine if the latter is
used with a particular vaporizer-O2-N2O fresh gas flow
sequence.
The performance of the Zeus® has been described in vitro,
and compared with the Primus® (Dräger, Lübeck, Ger-
many) [2]. The target desflurane FA was attained slightly
later with the Zeus® because part of the fresh gas goes
directly to the patient with the Primus®, while fresh gas is
extensively mixed in the circle system before reaching the
patient in the Zeus® [2]. The ADU® design (with the FGF
End-expired desflurane concentrations (FA, %) with the vaporizer-fresh gas flow sequence (ADU group) or with automated  closed-circuit anesthesia (Zeus® group) Figure 1
End-expired desflurane concentrations (FA, %) with the vaporizer-fresh gas flow sequence (ADU group) or 
with automated closed-circuit anesthesia (Zeus® group). Results are presented as mean ± standard deviation.BMC Anesthesiology 2008, 8:4 http://www.biomedcentral.com/1471-2253/8/4
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inflow located just distal to the inspiratory valve) also
explains the slightly faster rise of FA desflurane in the ADU
group. After wash-in, FA desflurane is maintained within a
slightly narrower range with the Zeus® than with the 0.7
L.min-1 FGF with the ADU® (figure 1). More details regard-
ing the performance characteristics of the FD-FGF
sequence can be found elsewhere [4].
Even though it is well known that the initial high FGF
period is a major determinant of vapor and gas consump-
tion, many anesthesiologists continue to use high FGF ini-
tially because low flow techniques have been perceived as
particularly cumbersome to use at the beginning of an
anesthetic. Because the initial wash-in and high uptake by
the patient rapidly alter the concentrations of anesthetic
gases in the circle system, the need for frequent vaporizer
and rotameters adjustments required when using low FGF
has been claimed to be too distracting at a time when the
anesthesiologist is preoccupied by other tasks. Like Lerou
[6], we therefore argue that a simple, clinically easy to
apply FD-FGF schedule as used in our ADU group could
encourage anesthesiologists to more frequently use lower
FGF early on during the anesthetic. With a conventional
machine with ascending visible bellows (e.g. the ADU®),
the acceptance of a small temporary bellows deficit allows
for early FGF reduction (after 3 min), and the small
amount of FGF in excess of patient uptake and gas sam-
pling during maintenance slowly washes out N2 yet con-
tributes little to overall desflurane consumption. The
somewhat unexpected finding that agent consumption is
higher with the Zeus® than with the ADU® is the result of
two factors: the use of a very high initial FGF (> 11 L/min)
and the intermittent flushing of the gas reservoir when N2
concentration reaches a certain threshold. The effect of the
first factor is readily demonstrated by calculating the effect
on desflurane consumption of shortening the high FGF
period by one min. With the described FD-FGF sequence
with the ADU®, desflurane consumption is 12.8 mL after
40 min; when the duration of high FGF is extended by one
min, total consumption increases to 14.4 mL. If the high
FGF would be extended by another 2 minutes, desflurane
consumption would become similar to that with the
Zeus®. The second important factor that explains the dif-
ference in agent consumption is the difference in the man-
ner the two techniques handle N2. With the conventional
anesthesia machine, gases sampled by the agent analyzer
Inspired O2 (FIO2), end-expired N2O (FAN2O), and inspired N2 (FIN2) concentrations with a conventional anesthesia machine  (ADU®) Figure 2
Inspired O2 (FIO2), end-expired N2O (FAN2O), and inspired N2 (FIN2) concentrations with a conventional 
anesthesia machine (ADU®). Results are presented as mean ± standard deviation.BMC Anesthesiology 2008, 8:4 http://www.biomedcentral.com/1471-2253/8/4
Page 5 of 6
(page number not for citation purposes)
(200 mL.min-1) are not redirected to the anesthesia circuit
(avoiding air entrainment by the gas analyzer into the cir-
cuit at a rate of 32 m L.min-1 [5]), and the 0.7 L.min-1
maintenance FGF used with the FD-FGF sequence there-
fore ensures that N2 concentration in the circuit remains
very low and even continues to decrease despite a rela-
tively short high FGF period (figure 2). The Zeus® takes a
different approach. As soon as possible and whenever
possible, it will try to convert to CCA conditions. Closing
the circuit will inevitable lead to a subsequent increase in
N2 in the anesthesia circuit because vessel rich tissues are
still releasing significant amounts of N2. Whenever the
FIN2  increases above a certain threshold (e.g. FIN2  of
15%), FGF is increased to flush the circuit (figure 3). Our
data indicate that serial flushing to reduce N2 increases
agent consumption well above the amount taken up by
the patient, to the extent that desflurane consumption
with our current FD-FGF sequence used with a conven-
tional anesthesia machine and a FGF in between minimal
flow (0.5 L.min-1) and low flow (1.0 L.min-1) becomes
lower than that with an automated closed-circuit anesthe-
sia machine, that – according to the definition of closed
circuit anesthesia – should administer just that amount of
agent that is taken up by the patient and lost via circuit
leaks. This suggests that administration regimens similar
to ours could help steer more conventional anesthesia
machines to lower agent consumption similar to or below
that of automated closed-loop feedback anesthesia
Example of fresh gas flow management by the Zeus® and resulting inspired O2 (FIO2), end-expired N2O (FAN2O), and N2 (FIN2)  concentrations Figure 3
Example of fresh gas flow management by the Zeus® and resulting inspired O2 (FIO2), end-expired N2O 
(FAN2O), and N2 (FIN2) concentrations. Note how during automated administration the FGF of O2 and N2O (right Y-axis, 
logarithmic scale) is increased whenever FIN2 increases above a threshold value of approximately 15% (grey arrows).
Table 1: Desflurane consumption (cumulative dose, mL liquid) 
was higher at all times (P < 0.05) during automated closed-
circuit anesthesia administration (Zeus®) than with a 
conventional machine used with the predefined low flow 
sequence (ADU®).
Time (min) ADU group Zeus group
0 0.0 ± 0.0 0.0 ± 0.0
5 6.0 ± 0.0 11.7 ± 4.0
10 7.1 ± 0.0 12.9 ± 4.1
15 8.2 ± 0.0 13.9 ± 4.2
20 9.1 ± 0.2 14.8 ± 4.5
25 10.0 ± 0.3 15.4 ± 4.3
30 11.0 ± 0.3 15.9 ± 4.5
35 11.9 ± 0.3 16.6 ± 4.6
40 12.8 ± 0.4 17.2 ± 4.8Publish with BioMed Central    and   every 
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machines, or could be used to optimize administration
algorithms of automated closed-loop feedback anesthesia
machines themselves. Agent consumption by the Zeus®
could be further reduced by optimizing the algorithm that
manages the initial FGF (e.g. by allowing a more gradual
rise towards the desired anesthetic gas concentrations) or
by tolerating some N2 in the circuit to minimize the need
for high FGF used during intermittent flushing. Our find-
ings also suggest that the actual FGFs used by a particular
technique or device should always be explicitly men-
tioned to allow proper interpretation of terms like
"closed-circuit".
Conclusion
Anesthetic agent consumption with an automated closed-
circuit anesthesia machine is higher than with a conven-
tional anesthesia machine if the latter is used with a spe-
cific vaporizer-FGF sequence. More specifically, one
desflurane vaporizer and one O2/N2O FGF change with a
conventional anesthesia machine with ascending visible
bellows suffices to maintain satisfactory anesthetic gas
concentrations within a clinically sufficiently narrow
range during the first 20–30 min in most patients. The
higher consumption with the closed-circuit anesthesia
machine is caused by the use of high FGF for initial circuit
and lung wash-in and by intermittent flushing of the cir-
cuit to reduce N2 accumulation. We therefore suggest that
agent consumption during automated delivery can be fur-
ther reduced by optimizing the algorithm(s) that manages
the initial FGF (e.g. by allowing a more gradual rise
towards the desired anesthetic gas concentrations) or by
tolerating some N2 in the circuit to minimize the need for
intermittent flushing.
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